Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment of both <i>Tsc2<sup>+/</sup></i><sup>-</sup> mice and a TSC1-null bladder cancer xenograft model with a CDK7 inhibitor showed marked reduction in tumor volume and absence of regrowth in the xenograft model.
|
31506280 |
2019 |
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity.
|
31645902 |
2019 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TSC1/2 mutations also occur in other neoplastic disorders, including lymphangioleiomyomatosis (LAM) and bladder cancer.
|
29669930 |
2018 |
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of TSC1 function, a crucial negative regulator of mTOR signaling, is a common alteration in bladder cancer.
|
27225870 |
2017 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, we observed that bladder cancer cell lines (RT4, UMUC-3, and J82) with homozygous deletion of either TSC1 or PTEN are more sensitive to metformin than those (TEU2, TCCSUP, and HT1376) with wild-type TSC1 and PTEN genes.
|
26921394 |
2016 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TSC1 c. 1907 1908 del (E636fs) mutation in bladder cancer suggests that the location of the mutation is Exon 15 with frequency of TSC1 mutation of 11.7 %.
|
27352265 |
2015 |
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used genomic sequencing to examine the involvement of TSC1 in bladder cancer, and signalling pathway analysis and small-molecule screening to identify targeted therapeutic strategies in TSC1 mutant bladder cancer cell lines.
|
23401075 |
2013 |
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
|
18480009 |
2008 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that although TSC1 missense mutations do not play a major role in causation of TSC disease, they represent a significant proportion of somatic loss of function mutations in bladder cancer.
|
18397877 |
2008 |
Carcinoma of bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent data suggest that functional inactivation of TSC proteins might also be involved in the development of other diseases not associated with TSC, such as sporadic bladder cancer, breast cancer, ovarian carcinoma, gall bladder carcinoma, non-small-cell carcinoma of the lung, and Alzheimer's disease.
|
16713332 |
2006 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mutation spectrum of TSC1 in bladder cancer and functional evidence from TSC1 -gene-replacement studies in bladder tumour cells will be presented.
|
12773163 |
2003 |
Carcinoma of bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This may indicate that haploinsufficiency for TSC1 can contribute to the development of bladder cancer and, if so, that the LOH of TSC1 observed in >50% of TCCs is biologically significant.
|
14633685 |
2003 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer.
|
11329144 |
2001 |
Carcinoma of bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the 9q34 gene TSC1 in sporadic bladder cancer.
|
10353610 |
1999 |
Carcinoma of bladder
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Carcinoma of bladder
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|